349 related articles for article (PubMed ID: 18475000)
1. Correcting Hatch-Waxman.
Fernandes M
Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
[No Abstract] [Full Text] [Related]
2. Congress works to permit 'biosimilar' drugs very soon.
Carroll J
Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
[No Abstract] [Full Text] [Related]
3. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
Behrendt KE
Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
[No Abstract] [Full Text] [Related]
4. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
5. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
6. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
7. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
8. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
Rea TS
Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
[No Abstract] [Full Text] [Related]
9. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
Steinhauer EH
Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
[No Abstract] [Full Text] [Related]
10. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
11. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
12. The response to health care reform by the pharmaceutical industry.
Krulwich AS
Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
[No Abstract] [Full Text] [Related]
13. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
14. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
15. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
16. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R; Wang C
N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
[No Abstract] [Full Text] [Related]
17. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
18. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
19. Antibiotics--an investment worth making?
Christoffersen RE
Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
[TBL] [Abstract][Full Text] [Related]
20. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
